Forcello, N., & Saraiya, N. (2014). Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL. J Adv Pract Oncol.
Čikaški stil citiranjaForcello, Nicholas, i Nidhi Saraiya. "Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL." J Adv Pract Oncol 2014.
MLA način citiranjaForcello, Nicholas, i Nidhi Saraiya. "Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL." J Adv Pract Oncol 2014.
Upozorenje: Ovi citati možda nisu uvijek 100% točni.